3720 Spectrum Blvd., Suite 125, Tampa, FL 33612

Our Pipeline

An overview of the products being researched, developed, and a brief summary of our pipeline.

pipeline

Chronic diseases continue to be underserved by the current, prevalent mono-therapeutic approaches (which are partially effective at best), creating persisting unmet medical needs.  Our objective is to select for and bring to market, clinically differentiated, superior combination nanomedicines that mitigate unmet medical needs in large therapeutic areas to create maximal patient impact.

Current Pipeline

* Human PoC – Human Proof-of-Concept Study, Open-label, Non-Randomized

** Pre-IND meeting with USFDA completed, feedback on Phase 3 Clinical Development plan obtained

Three Clinical POC Studies

Studies demonstrating Superiority Vs. “Standard of Care,” Establish & De-Risk the MNP Platform.


A Head-to-Head, Randomized, Controlled, Clinical Study Demonstrates Superiority of SGN’s MNP-Cyclosporine (SGN-101) vs the Current "Standard of Care" RESTASIS

In a study (published by BMC Ophthalmology) for Dry Eye Disease (DED), MNP Cyclosporine was (1) statistically superior to Restasis beginning 4 weeks of treatment and (2) more tolerable.

Current/Future Step(s):

  1. Guidance for Phase 3 studies has been received from the USFDA.
  2. We are in active out-licensing discussions with potential partners and expect to complete the out-licensing in 2H 2023.


Pain topical nanolotion (SGN-624)

SGN-624 comprises a transdermal, fixed-dose combination of two active pharmaceutical ingredients targeting inflammatory and neuropathic components of pain.

SGN-624 demonstrated significant efficacy in an open-label, single-center study involving 94 patients with advanced, medically refractory chronic knee osteoarthritis (OA) and spinal pain. At baseline, 97.9% of patients were taking oral NSAIDs and 69.1% were taking opioids.

Treatment: High-dose GM-624 nanolotion applied twice daily for 15 days to 3 months.


Key Results (all p < 0.0001)

  • 69.9% achieved maximum pain relief; 77.4% achieved at least moderate-to-maximum relief.
  • 50.8% functional improvement: Among the 72 patients eligible for WOMAC analysis, the mean score decreased by 27.9 points from a baseline mean of 55.
  • 100% NSAID discontinuation: All 92 NSAID users stopped completely, with discontinuation reported across every subgroup.
  • 100% opioid benefit: 70.8% discontinued opioids entirely, while 29.2% reduced their dosage. No patients reported having no benefit.

Current / Future Steps

  1. Guidance for Phase 3 studies has been received from the USFDA.
  2. Animal toxicology studies requested by the FDA are underway.
  3. Plan to launch Phase 2 studies in acute pain in 2H 2027 and Phase 3 studies in chronic pain by year-end (YE) 2027.


MNP Topical nano-lotion for treatment of Diabetic Neuropathy (SGN-516)

In a recently concluded two-center, open-label study involving 19 patients with uncontrolled diabetic neuropathy treated with SGN-516, 15 of the 19 patients experienced a 50–80% improvement from baseline within one month of treatment.

In addition, 4 patients who had experienced loss of tactile sensation in their fingertips (3 patients) or feet (1 patient) recovered sensory perception within 3 months of treatment initiation.


Current / Future Steps

  1. Initiate a controlled, 80-patient study in the second half of 2027.
  2. FDA-requested animal toxicology studies are underway.